Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
|Videos|November 27, 2017
Dr. Gainor Discusses the Future of EGFR+ NSCLC
Author(s)Justin F. Gainor, MD
Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.
Advertisement
Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer (NSCLC).
The results of FLAURA are convincing enough to suggest that osimertinib (Tagrisso) should be first-line treatment of choice for these patients, says Gainor.
Moving forward, better understanding response and resistance to osimertinib should be a priority, Gainor adds.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5